• Monopar Therapeutics posted a net loss of USD 3.89 million for Q1 ended March 31, 2026, widening from USD 2.62 million a year earlier.
• Operating loss widened to USD 5.23 million, while total operating expenses climbed to USD 5.23 million.
• Research and development expenses more than doubled to USD 3.49 million, while general and administrative costs rose 10.11% to USD 1.74 million.
• Interest income jumped to USD 1.33 million, reflecting higher balances following net proceeds of about USD 91.9 million from a September 2025 capital raise.
• Cash, cash equivalents and investments totaled USD 137.5 million at March 31, 2026; Monopar expects current funds to last at least through Dec. 31, 2027, while targeting a mid-2026 NDA submission for ALXN1840 in Wilson disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-016982), on May 14, 2026, and is solely responsible for the information contained therein.